DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
60	再生不良性貧血	3

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02918292 (ClinicalTrials.gov)	July 3, 2017	27/9/2016	Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)	Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP) (BMT CTN #1502)	Severe Aplastic Anemia	Drug: Antithymocyte Globulin (ATG);Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation (TBI);Procedure: Haplo HSCT;Drug: Tacrolimus;Drug: Mycophenolate mofetil (MMF);Drug: G-CSF	Medical College of Wisconsin	National Heart, Lung, and Blood Institute (NHLBI);National Cancer Institute (NCI);Blood and Marrow Transplant Clinical Trials Network;National Marrow Donor Program	Recruiting	N/A	75 Years	All	30	Phase 2	United States
2	NCT01163942 (ClinicalTrials.gov)	March 2001	14/7/2010	Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)	A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF	Aplastic Anaemia	Drug: G-CSF;Drug: Early retreatment with ATG	European Group for Blood and Marrow Transplantation	CHUGAI sanofi-aventis	Terminated	N/A	N/A	Both	205	Phase 3	Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom
3	NCT00001964 (ClinicalTrials.gov)	December 2, 1999	18/1/2000	Combination Therapy of Severe Aplastic Anemia	Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)	Severe Aplastic Anemia	Drug: Cyclosporine A;Drug: ATG;Drug: MMF	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	1 Year	99 Years	All	104	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02918292
(ClinicalTrials.gov)

July 3, 2017

27/9/2016

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP) (BMT CTN #1502)

Severe Aplastic Anemia

Drug: Antithymocyte Globulin (ATG);Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation (TBI);Procedure: Haplo HSCT;Drug: Tacrolimus;Drug: Mycophenolate mofetil (MMF);Drug: G-CSF

Medical College of Wisconsin

National Heart, Lung, and Blood Institute (NHLBI);National Cancer Institute (NCI);Blood and Marrow Transplant Clinical Trials Network;National Marrow Donor Program

Recruiting

N/A

75 Years

All

Phase 2

United States

NCT01163942
(ClinicalTrials.gov)

March 2001

14/7/2010

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF

Aplastic Anaemia

Drug: G-CSF;Drug: Early retreatment with ATG

European Group for Blood and Marrow Transplantation

CHUGAI sanofi-aventis

Terminated

N/A

Both

205

Phase 3

Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom

NCT00001964
(ClinicalTrials.gov)

December 2, 1999

18/1/2000

Combination Therapy of Severe Aplastic Anemia

Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)

Severe Aplastic Anemia

Drug: Cyclosporine A;Drug: ATG;Drug: MMF

National Heart, Lung, and Blood Institute (NHLBI)

NULL

Completed

1 Year

99 Years

All

104

Phase 2

United States